• 1
    Wong CW, Song C, Grimes MM, Fu W, Dewhirst MW, Muschel RJ, Al-Mehdi AB. Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am J Pathol 2002; 161: 74953.
  • 2
    Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003; 3: 4538.
  • 3
    Monzavi-Karbassi B, Whitehead TL, Jousheghany F, Artaud C, Hennings L, Shaaf S, Slaughter A, Korourian S, Kelly T, Blaszczyk-Thurin M, Kieber-Emmons T. Deficiency in surface expression of E-selectin ligand promotes lung colonization in a mouse model of breast cancer. Int J Cancer 2005; 117: 398408.
  • 4
    Krause T, Turner GA. Are selectins involved in metastasis? Clin Exp Metastasis 1999; 17: 18392.
  • 5
    Nelson RM, Venot A, Bevilacqua MP, Linhardt RJ, Stamenkovic I. Carbohydrate–protein interactions in vascular biology. Annu Rev Cell Dev Biol 1995; 11: 60131.
  • 6
    Majuri ML, Niemela R, Tiisala S, Renkonen O, Renkonen R. Expression and function of α2,3-sialyl- and α1,3/1,4-fucosyltransferases in colon adenocarcinoma cell lines: role in synthesis of E-selectin counter-receptors. Int J Cancer 1995; 63: 5519.
  • 7
    Renkonen J, Paavonen T, Renkonen R. Endothelial and epithelial expression of sialyl Lewis (x) and sialyl Lewis (a) in lesions of breast carcinoma. Int J Cancer 1997; 74: 296300.
  • 8
    Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA 1998; 95: 932530.
  • 9
    Ohyama C, Tsuboi S, Fukuda M. Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells. EMBO J 1999; 18: 151625.
  • 10
    Biancone L, Araki M, Araki K, Vassalli P, Stamenkovic I. Redirection of tumor metastasis by expression of E-selectin in vivo. J Exp Med 1996; 183: 5817.
  • 11
    Varki A. Selectin ligands: will the real ones please stand up? J Clin Invest 1997; 100: S31S5.
  • 12
    Ogawa J, Sano A, Koide S, Shohtsu A. Relation between recurrence and expression of proliferating cell nuclear antigen, sialyl LewisX, and sialyl Lewis(a) in lung cancer. J Thorac Cardiovasc Surg 1994; 108: 32936.
  • 13
    Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, Izumi Y, Irimura T. Involvement of carbohydrate antigen sialyl Lewis (x) in colorectal cancer metastasis. Dis Colon Rectum 1997; 40: 42031.
  • 14
    Baldus SE, Zirbes TK, Monig SP, Engel S, Monaca E, Rafiqpoor K, Hanisch FG, Hanski C, Thiele J, Pichlmaier H, Dienes HP. Histopathological subtypes and prognosis of gastric cancer are correlated with the expression of mucin-associated sialylated antigens: sialosyl-Lewis(a), sialosyl-Lewis(x) and sialosyl-Tn. Tumour Biol 1998; 19: 44553.
  • 15
    Stone JP, Wagner DD. P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. J Clin Invest 1993; 92: 80413.
  • 16
    Sawada R, Tsuboi S, Fukuda M. Differential E-selectin-dependent adhesion efficiency in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem 1994; 269: 142531.
  • 17
    Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98: 33527.
  • 18
    Fukuda MN, Ohyama C, Lowitz K, Matsuo O, Pasqualini R, Ruoslahti E, Fukuda M. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res 2000; 60: 4506.
  • 19
    Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost 2002; 28: 5366.
  • 20
    O I, Otvos L, Kieber-Emmons T, Blaszczyk-Thurin M. Role of SA-Le(a) and E-selectin in metastasis assessed with peptide antagonist. Peptides 2002; 23: 9991010.
  • 21
    Fuster MM, Brown JR, Wang L, Esko JD. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res 2003; 63: 277581.
  • 22
    Wei M, Tai G, Gao Y, Li N, Huang B, Zhou Y, Hao S, Zeng X. Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions. J Biol Chem 2004; 279: 2920210.
  • 23
    Giavazzi R, Foppolo M, Dossi R, Remuzzi A. Rolling and adhesion of human tumor cells on vascular endothelium under physiological flow conditions. J Clin Invest 1993; 92: 303844.
  • 24
    Mannori G, Crottet P, Cecconi O, Hanasaki K, Aruffo A, Nelson RM, Varki A, Bevilacqua MP. Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Res 1995; 55: 442531.
  • 25
    Goetz DJ, Ding H, Atkinson WJ, Vachino G, Camphausen RT, Cumming DA, Luscinskas FW. A human colon carcinoma cell line exhibits adhesive interactions with P-selectin under fluid flow via a PSGL-1-independent mechanism. Am J Pathol 1996; 149: 166173.
  • 26
    Pottratz ST, Hall TD, Scribner WM, Jayaram HN, Natarajan V. P-selectin-mediated attachment of small cell lung carcinoma to endothelial cells. Am J Physiol 1996; 271: L918L23.
  • 27
    Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998; 12: 124151.
  • 28
    Ma YQ, Geng JG. Heparan sulfate-like proteoglycans mediate adhesion of human malignant melanoma A375 cells to P-selectin under flow. J Immunol 2000; 165: 55865.
  • 29
    Ma YQ, Geng JG. Obligatory requirement of sulfation for P-selectin binding to human salivary gland carcinoma Acc-M cells and breast carcinoma ZR-75-30 cells. J Immunol 2002; 168: 16906.
  • 30
    Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998; 58: 148693.
  • 31
    Sanderson RD. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 2001; 12: 8998.
  • 32
    Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ, Kelly T, Sanderson RD. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 2005; 105: 13039.
  • 33
    Hirabayashi K, Numa F, Suminami Y, Murakami A, Murakami T, Kato H. Altered proliferative and metastatic potential associated with increased expression of syndecan-1. Tumour Biol 1998; 19: 45463.
  • 34
    Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 87789.
  • 35
    Kawashima H, Hirose M, Hirose J, Nagakubo D, Plaas AH, Miyasaka M. Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J Biol Chem 2000; 275: 3544856.
  • 36
    Kawashima H, Atarashi K, Hirose M, Hirose J, Yamada S, Sugahara K, Miyasaka M. Oversulfated chondroitin/dermatan sulfates containing GlcAβ1/IdoAα1-3GalNAc(4,6-O-disulfate) interact with L- and P-selectin and chemokines. J Biol Chem 2002; 277: 1292130.
  • 37
    Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, Nicholas RW, Suva LJ. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 2002; 62: 55719.
  • 38
    Fukushi Y, Nudelman E, Levery SB, Hakomori S, Rauvala H. Novel fucolipids accumulating in human adenocarcinoma. III. A hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside (VI3Neu. Ac. V3III3Fuc2n. Lc6). J Biol Chem 1984; 259: 105117.
  • 39
    Fukushima K, Hirota M, Terasaki PI, Wakisaka A, Togashi H, Chia D, Suyama N, Fukushi Y, Nudelman E, Hakomori S. Characterization of sialosylated Lewisx as a new tumor-associated antigen. Cancer Res 1984; 44: 527985.
  • 40
    Hanai N, Shitara K, Yoshida H. Generation of monoclonal antibodies against human lung squamous cell carcinoma and adenocarcinoma using mice rendered tolerant to normal human lung. Cancer Res 1986; 46: 443843.
  • 41
    Dohi T, Nemoto T, Ohta S, Shitara K, Hanai N, Nudelman E, Hakomori S, Oshima M. Different binding properties of three monoclonal antibodies to sialyl Le (x) glycolipids in a gastric cancer cell line and normal stomach tissue. Anticancer Res 1993; 13: 127782.
  • 42
    Kanoh A, Ota M, Narimatsu H, Irimura T. Expression levels of FUT6 gene transfected into human colon carcinoma cells switch two sialyl-Lewis X-related carbohydrate antigens with distinct properties in cell adhesion. Biochem Biophys Res Commun 2003; 303: 896901.
  • 43
    David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol 1992; 119: 96175.
  • 44
    Safaiyan F, Kolset SO, Prydz K, Gottfridsson E, Lindahl U, Salmivirta M. Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate. J Biol Chem 1999; 274: 3626773.
  • 45
    Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991; 252: 17058.
  • 46
    Santiago B, Baleux F, Palao G, Gutierrez-Canas I, Ramirez JC, Arenzana-Seisdedos F, Pablos JL. CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans. Arthritis Res Ther 2006; 8: R43.
  • 47
    Skinner MP, Fournier DJ, Andrews RK, Gorman JJ, Chesterman CN, Berndt MC. Characterization of human platelet GMP-140 as a heparin-binding protein. Biochem Biophys Res Commun 1989; 164: 13739.
  • 48
    Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80: 1023.
  • 49
    Engelberg H. Actions of heparin that may affect the malignant process. Cancer 1999; 85: 25772.
  • 50
    Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999; 91: 2236.
  • 51
    Kim YJ, Borsig L, Han HL, Varki NM, Varki A. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am J Pathol 1999; 155: 46172.
  • 52
    Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001; 53: 93105.
  • 53
    Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins–correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005; 11: 700311.
  • 54
    Couchman JR, Caterson B, Christner JE, Baker JR. Mapping by monoclonal antibody detection of glycosaminoglycans in connective tissues. Nature 1984; 307: 6502.
  • 55
    Irwin MH, Mayne R. Use of monoclonal antibodies to locate the chondroitin sulfate chain(s) in type IX collagen. J Biol Chem 1986; 261: 162813.
  • 56
    Honke K, Taniguchi N. Sulfotransferases and sulfated oligosaccharides. Med Res Rev 2002; 22: 63754.
  • 57
    Kobzdej MM, Leppanen A, Ramachandran V, Cummings RD, McEver RP. Discordant expression of selectin ligands and sialyl Lewis x-related epitopes on murine myeloid cells. Blood 2002; 100: 448594.
  • 58
    Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA 2002; 99: 21938.
  • 59
    Cosgrove RH, Zacharski LR, Racine E, Andersen JC. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost 2002; 28: 7987.